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Introduction
Hospital-acquired pneumonia (HAP) is a respiratory
infection which occurs 48 hours after hospital admis-
sion. It is an important cause of hospital morbidity,
observed most frequently in medical wards and in 
elderly patients with severe underlying illnesses. HAP
is the second most frequent cause of nosocomial in-
fection, accounting for 15–20% of such infections1. It
occurs in 0.5–1.5% of inpatients and is usually caused
by bacteria.
HAP accounts for more than 50% of all antibiotics
prescribed2. It is currently the most common infection
contributing to high mortality and morbidity3. HAP is
the leading cause of death among hospital-acquired
infections, with the crude mortality rate for HAP per-
haps as high as 20–71%, but many of the patients with
HAP die of their underlying disease rather than pneu-
monia4. An increase in mortality attributable to HAP is
related to the presence of multidrug-resistant (MDR)
pathogens. The clinical characteristics of pneumonia in
the elderly differ substantially from those in younger
patients, and the severity of the disease is, therefore,
strongly associated with increased age and age-related
comorbidities5. Moreover, the length of hospital stay
and the mortality rate are significantly higher in the
elderly6. The time of onset of pneumonia and risk fac-
tors for specific patients with HAP are variable. The
microbial etiology of pneumonia may also vary with age
and care setting, resulting in the need to adequately
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amend the antibiotic choice in the elderly. Aspiration
pneumonia is also an important clinical feature in eld-
erly patients suffering from cerebrovascular disorder-
associated dysphagia7.
Risk Factors and Prognosis
The parameters associated with an increased risk of
pneumonia include alcoholism, swallowing disorders,
male gender, age greater than 60 years, neoplasms,
chronic obstructive pulmonary disease (COPD), diabe-
tes, heart failure, immunosuppression, intubation, and
prolonged ventilation8–11. Low serum albumin is also
one of the predictors for pneumonia developing in the
elderly, and malnutrition is more often found in elderly
patients with pneumonia11.
There are different risk factors for HAP with varied
pathogens. Risk factors for infection with Streptococcus
pneumoniae include >65 years, β-lactam therapy with-
in the previous 3 months, alcoholism, cirrhosis, chronic
cardiovascular or pulmonary disease, diabetes melli-
tus, corticosteroid use, multiple comorbidities, func-
tional or anatomic asplenia, cerebrospinal fluid leak,
and immunosuppressive disorder or treatment12. Risk
factors for enteric Gram-negative rods include nursing
home residence, cardiopulmonary disease, multiple co-
morbidities, and recent antibiotic therapy. Infection by
Pseudomonas aeruginosa is associated with a number
of risk factors that are not associated with age but with
structural lung diseases, recent antibiotic treatment,
broad spectrum antibiotic use for more than 7 days in
the last month, malnutrition, and prednisone >10 mg/
day. Risk factors for infection with Staphylococcus aureus
include end-stage renal disease, injection drug abuse,
prior influenza, and prior antibiotic use (particularly
fluoroquinolones), diabetes mellitus, head trauma, and
intubation10,13.
Conditions known to increase mortality include pro-
longed mechanical ventilatory support, an underlying
fatal condition, age greater than 60 years, bilateral radio-
graphic infiltrates, prior antibiotic therapy, prior pneu-
monia with superinfection, chronic lung disease, low
body mass index, Gram-negative bacilli, polymicrobial
flora, and microbes that have acquired antibiotic resis-
tance14–16. Increased mortality rates were also associated
with bacteremia, especially with P. aeruginosa or Acineto-
bacter species, medical rather than surgical disease,
and therapy with ineffective antibiotic treatment15,17.
Etiology
HAP may be caused by a wide spectrum of bacterial
pathogens, and is more frequently polymicrobial in
ventilator-associated pneumonia18. HAP is rarely caused
by viral or fungal pathogens in immunocompetent
patients8,19. It has been established that colonization
dramatically increases in patients with acidosis, alco-
holism, azotemia, coma, diabetes mellitus, hypotension,
leukocytosis, leukopenia, pulmonary disease, endotra-
cheal or nasogastric intubation, and in patients given
antimicrobial agents20,21. With gastric pH > 4, microor-
ganisms are able to increase to high concentrations in
the stomach22. This can happen in patients with ad-
vanced age, achlorhydria, ileus, upper gastrointestinal
disease, enteral feeding, antacids, and histamine2 (H2)
antagonists22,23. Impaired intestinal motility is also
attributed to gastric colonization in patients24. In addi-
tion, certain conditions such as malnutrition, severe ill-
ness or post-operative state can increase the adherence
of Gram-negative bacteria25. There are a number of fac-
tors that enhance colonization of the oropharynx and/or
stomach by microbes, including administration of antimi-
crobial agents, presence of underlying chronic lung dis-
ease, prolonged mechanical ventilatory support, contact
with contaminated or colonized hands, extreme old age,
malnutrition, severe underlying conditions, and immu-
nosuppression26,27. The high incidence of Gram-negative
bacillary pneumonia in hospitalized patients appears
to be the result of factors that promote colonization of
the pharynx by Gram-negative bacilli and the subse-
quent entry of these microorganisms into the lower
respiratory tract21.
Early-onset HAP occurs within the first 4 days of
hospitalization and usually has a better prognosis. Early-
onset HAP without risk factors for MDR is often caused
by typical antimicrobial-susceptible organisms such as
S. pneumoniae, Haemophilus influenzae, methicillin-
sensitive S. aureus, and antibiotic-sensitive enteric Gram-
negative bacilli (Escherichia coli, Klebsiella pneumoniae,
Enterobacter species, Proteus species, and Serratia marce-
scens)28. Several studies have demonstrated that pneumo-
nia caused by Mycoplasma pneumoniae is less common
in elderly patients29, and viruses, mainly influenza and
the respiratory syncytial virus, also play a role in the
occurrence of pneumonia in the elderly30.
Silent aspiration during sleep seems to happen more
frequently in elderly people with pneumonia, regardless
of neurologic disorders31. Aspiration of nasopharyngeal
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or gastric contents is a frequent occurrence among el-
derly patients, being related mainly to neurologic dis-
orders that cause dysphagia and decreased cough
reflex32. Persons with abnormal swallowing, such as
those who have depressed consciousness, respiratory
tract instrumentation, gastrointestinal tract instrumen-
tation, or who have just undergone surgery, especially
thoracic and/or abdominal surgery, are particularly
prone to aspiration19,33. An acute cerebrovascular dis-
order seems to be the most common cause of swallow-
ing difficulties. Up to 80% of these patients present
with dysphagia, and 40–50% develop aspiration pneu-
monia32. It has been reported that the oral hygiene in
the elderly is frequently poor, facilitating the develop-
ment of abundant oral flora that can induce further
airway colonization and infection34. Furthermore, the
elderly tend to develop poor functional status and feed-
ing problems, which further increases the risk of aspi-
ration pneumonia35. The diagnosis of pneumonia in
elderly persons with cerebrovascular disease and swal-
lowing difficulties should take into account possible
aspiration and provide for wide antimicrobial cover-
age, including anaerobes and enteric Gram-negative
bacteria. HAP involving anaerobic organisms may follow
aspiration in non-intubated patients, but is rare in intu-
bated patients36.
The most common pathogens of late HAP are 
P. aeruginosa, S. aureus, Enterobacteriaceae (especially
Klebsiella, E. coli and Enterobacter species), and methi-
cillin-resistant S. aureus (MRSA)8,37. The longer a patient
is in hospital, the wider the spectrum of likely patho-
gens and the more likely they are to be MDR. Late-onset
HAP (5 days or more) is more likely to be caused by
MDR organisms, and is associated with increased mortal-
ity and morbidity. The risk factors of MDR pathogens in-
clude being hospitalized in an acute care hospital for 
2 days or more in the preceding 90 days, prior antibiotic
use especially broad-spectrum drugs (a third-generation
cephalosporin, a fluoroquinolone, and/or a carbape-
nem), being resident in a nursing home or extended
care facility, having received recent intravenous antibi-
otic therapy, chronic dialysis within the past 30 days,
home wound care within the past 30 days, current hos-
pitalization of 5 days or more, a family member with
MDR, and immunosuppression4,38.
The bacteriology of HAP in non-ventilated patients
is similar to that in ventilated patients, including aero-
bic Gram-negative bacilli, P. aeruginosa, K. pneumoniae,
Acinetobacter species, as well as Gram-positive cocci,
such as S. aureus, much of which is MRSA; anaerobes
are an uncommon cause of ventilator-associated
pneumonia8,36. Some microbes, such as MRSA and K.
pneumonia, are more common in non-ventilated than
ventilated patients, whereas certain resistant Gram-
negative bacilli are more common in patients with
ventilator-associated pneumonia (P. aeruginosa, Stenotro-
phomonas maltophilia, and Acinetobacter species). In
one study of 52 patients aged 70 years who failed to
respond to 72 hours of antibiotics, MRSA (33%), Gram-
negative enterics (24%) and Pseudomonas species (14%)
were the most frequent pathogens isolated by bron-
choscopy. It was noted that 72% had at least two
comorbidities, whereas 23% had three or more39. The
frequency of specific MDR pathogens causing HAP may
vary by hospital, patient population, exposure to anti-
biotics, type of intensive care unit patient and changes
over time, addressing the need for timely, local sur-
veillance data8,15,37,40.
Environmental microorganisms such as Legionella
species and Aspergillus species should be considered
in HAP in patients not receiving ventilation. Legionella
pneumophila is increased in immunocompromised
hosts, such as organ transplant recipients, human immu-
nodeficiency virus disease, diabetes mellitus, underly-
ing lung disease, and end-stage renal disease41. HAP
due to Legionella species is more common in hospitals
where the pathogen is present in the hospital water
supply. Detection is based on the widespread use of
Legionella urinary antigen. Disease due to serogroups
other than serogroup 1 may be underdiagnosed.
Controlling the risk of Legionella in hospital water sup-
plies decreases the risk of Legionella pneumonia.
Evaluation and Diagnosis
It is difficult to diagnose HAP. Traditional criteria, such
as fever, cough, sputum production and pleuritic chest
pain, are not sufficiently accurate to confirm pneumo-
nia. The clinical presentation of pneumonia in older
patients is often without the typical acute symptoms
observed in young adults42. This clinical paucity causes
a delay of diagnosis by ≥ 72 hours, contributing to fur-
ther mortality. However, altered mental status (delir-
ium) may be a common manifestation of pneumonia
in older patients43. Both clinical features and physical
findings may be lacking or misrepresented in elderly
patients. All patients should be screened by pulse
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oximetry, which may imply the presence of pneumo-
nia in patients without obvious signs of pneumonia44.
In addition, elderly patients with pneumonia are more
likely to have an unclear pulmonary infiltrate on chest
radiography45. For patients with suspected pneumonia
but who have negative chest radiography findings, it
may be reasonable to treat their condition presump-
tively with antibiotics and repeat the imaging in 24–48
hours. Chest tomographies may be more sensitive46. The
presence of a new or progressive radiographic infiltrate
with at least two of three clinical features, fever greater
than 38°C, leukocytosis or leukopenia, and purulent
secretions, represent the most accurate clinical criteria
for beginning empirical antibiotic therapy47. Direct
staining is a simple procedure, providing valuable
information within 1 hour. A reliable Gram stain can
be used to guide initial antibiotic therapy and may
increase the diagnostic value of the clinical pulmonary
infection score (CPIS)48,49. Reevaluation of the decision
to use antibiotics according to the results of semiquan-
titative lower respiratory tract cultures and serial clinical
evaluations is necessary by day 3 or sooner50. A CPIS 
of 6 or less for 3 days is an objective criterion to select
patients at low risk for early discontinuation of empirical
therapy for HAP51.
The application of noninvasive diagnostic tests did
not allow us to determine the importance of microor-
ganisms that are normal oropharyngeal flora or which
colonize hospitalized patients. The etiologic diagnosis
was only established in one-third of the cases of HAP
in noncritical patients because of the inability to per-
form invasive procedures in most of the patients52.
If bronchoscopic sampling is not immediately avail-
able, non-bronchoscopic sampling can reliably get lower
respiratory tract secretions for quantitative cultures,
which can be used to guide antibiotic therapy53. Invasive
sampling methods involve bronchoscopic techniques
to obtain quantitative cultures of protected specimen
brush and bronchoalveolar lavage. The reported sensi-
tivities and specificities of these methods range from
70–100% and 60–100%, respectively, depending on the
tests or diagnostic criteria with which they are com-
pared54,55. A major factor causing false-negative quan-
titative cultures is the recent initiation of, or change in,
antimicrobial therapy, especially in the prior 24 hours,
but up to 72 hours56,57. The threshold of quantitative cul-
tures of protected specimen brush is 103 colony-forming
unit/mL or more. The threshold of bronchoalveolar
lavage is 104 or 105 colony-forming unit/mL, and the
advantage of looking for intracellular organisms is the
ability to obtain data of high predictive value in a rapid
time frame. The diagnostic threshold may be lowered
if the patient has had changes in antibiotic therapy
recently or if the probability of infection is high. Soluble
triggering receptor expressed on myeloid cells coupled
with the classic clinical criteria and results of microbi-
ologic cultures may be a valuable tool with which to
enhance the specificity and maintain the sensitivity of
HAP diagnosis58. Delays in the initiation of appropri-
ate antibiotic therapy can increase the mortality and,
therefore, therapy should not be postponed for the
purpose of performing diagnostic studies in patients who
are clinically unstable59. Clinically unstable patients
with signs of infection should receive therapy, in spite
of initial bronchoscopic findings56. The use of lung tis-
sue for diagnosis of pneumonia is not recommended
in most ventilated patients; it can, however, be useful
in some immunocompromised patients60.
Treatment
It is widely presumed that treatment outcomes for HAP
will be affected by the susceptibilities of the infecting
organisms. Treatment should be administered as soon
as possible after the diagnosis is considered probable,
especially in cases of severe HAP. Early proper antibi-
otic therapy improves the outcome of HAP with a
lower attributable mortality. There is a survival benefit
to increasing the percentage of patients who receive
antibiotics within the first 4–8 hours61. Early appropri-
ate broad-spectrum antimicrobial treatment should
be prescribed with sufficient doses to optimize antibi-
otic efficacy. Therapies which the patients have received
within the previous 2 weeks should also be consid-
ered, avoiding use of the same antimicrobial class,
when possible. Microbiologic results may come too late
to influence outcome, and broad-spectrum empirical
antimicrobial therapy is often used before microbio-
logic diagnosis is confirmed62. A lower respiratory tract
culture needs to be collected before antimicrobial
treatment, but collection of cultures should not defer
the initiation of therapy in critically ill patients. Either
“quantitative” or “semiquantitative” culture data can be
used for the treatment of patients with HAP. Quan-
titative cultures increase specificity of the diagnosis of
HAP without negative effects, and the specific quanti-
tative technique should be selected on the basis of
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local expertise and experience. Specimens obtained after
initiation of antimicrobial treatment are unreliable
and must be interpreted carefully.
Negative lower respiratory tract cultures can be
used to discontinue antimicrobial therapy in a patient
who has had cultures performed in the absence of an
antimicrobial change in the past 72 hours. A clinical
protocol utilizing CPIS ≤6 would regard elderly patients
at low risk of HAP, suitable for early discontinuation 
of empirical antimicrobial treatment for HAP on the
third day51. Clinical improvement usually takes 48–
72 hours and, thus, treatment should not be changed
during this time unless there is a rapid clinical deterio-
ration. De-escalation of antimicrobials should be consid-
ered once data becomes available regarding the results
of lower respiratory tract cultures and the patient’s
clinical response. Use of a shorter duration of antimi-
crobial therapy (7–8 days) is suggested for patients
with uncomplicated HAP who have received initially
appropriate treatment and have had a good clinical
response63. There is no evidence on the conversion of
intravenous treatment to oral treatment in the man-
agement of HAP, and these decisions must, therefore,
be taken on a case-by-case basis according to the clin-
ical response to therapy. Inadequate treatment of HAP
should be avoided, because the failure to initiate
prompt proper and sufficient treatment has been a
factor associated with increased mortality.
Inappropriate antimicrobial treatment has also been
associated with a lack of clinical improvement in the
CPIS, particularly in serial measurements of arterial
oxygenation61. For patients who are deteriorating quickly
(e.g., fever with temperature >38.3°C, circulating leuko-
cyte count > 10,000 mm3, lack of improvement in the
chest radiograph, continued purulent sputum) and
not responding to initial treatment, it may be neces-
sary to broaden antimicrobial coverage while waiting
for the results of cultures and other diagnostic studies.
Mismatch between the susceptibility of common caus-
ative pathogens, infection with a microbe not covered
by the usual empirical treatment, and nosocomial super-
infection pneumonia are major causes of obvious anti-
microbial failure. No response may also be mimicked by
coexistent subsequent extrapulmonary infection, such
as intravascular catheter-related infections, urinary,
abdominal and skin infections. Appropriate cultures of
these sites are taken into account for patients that are
non-responsive. In addition to microbiologic diagnos-
tic procedures, other tests such as chest tomography
appear to be helpful for selected patients. Chest tomog-
raphy can reveal other reasons for antibiotics, including
pleural effusions, lung abscess, obstruction or bronchi-
olitis obliterans with organizing pneumonia.
The finding of a rapidly deteriorating radiographic
pattern, with a follow-up chest radiograph revealing
progression to multilobar involvement, a greater than
50% increase in the size of the infiltrate within 48
hours, development of cavitary disease, or significant
pleural effusion, should raise concern17. Radiographic
improvement usually lags behind clinical parameters,
especially in the elderly and in individuals with comor-
bidities (e.g., COPD)50. The radiologic resolution is sig-
nificantly delayed in patients with a high comorbidity
index, bacteremia, multilobar involvement, and Gram-
negative microorganisms63,64. Elderly patients with more
chronic comorbidities may need a longer duration of
therapy until complete resolution of pneumonia-related
symptoms is achieved65.
Early-onset HAP without risk factors for MDR path-
ogens is usually caused by antimicrobial-susceptible
microbes such as S. pneumoniae, H. influenzae, 
methicillin-sensitive S. aureus, and antibiotic-sensitive
enteric Gram-negative bacilli (E. coli, K. pneumoniae,
Enterobacter species, Proteus species, and S. marcescens).
Therapeutic choices of early-onset HAP without risk fac-
tors for MDR pathogens include ceftriaxone or levoflo-
xacin, moxifloxacin, ciprofloxacin, ampicillin/sulbactam,
or ertapenem. Presently, many strains of S. pneumoniae
are penicillin resistant66. Despite low and moderate
resistance to penicillins and cephalosporins in vitro,
clinical results in patients with pneumococcal pneu-
monia and bacteremia treated with these antibiotics
have been satisfactory66. The MDR pneumococci are
currently sensitive to vancomycin or linezolid, and
most remain sensitive to broad-spectrum quinolones.
The overuse of fluoroquinolones has also resulted in
the emergence of fluoroquinolone-resistant pneumo-
cocci67. The advantage of combination therapy is most
striking in the more severely ill patients68.
Klebsiella species are intrinsically resistant to amino-
penicillins and can obtain resistance to cephalosporins
and aztreonam by the production of extended-spectrum
β-lactamases69. Plasmid mediated resistance, such as
extended-spectrum β-lactamase production, is a more
common mechanism for β-lactam resistance in nosoco-
mial isolates, and is increasingly recognized in isolates
of K. pneumoniae and E. coli, and Enterobacter species70.
Use of a fourth-generation cephalosporin such as
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cefepime for this infection is disputed71. A reliable option
is a carbapenem, which is generally active against these
pathogens72. Piperacillin–tazobactam against microbes
with extended-spectrum β-lactamase is unpredictable
and should be used at adequate doses73.
A clinical distinction between pneumonia and aspi-
ration pneumonitis may be important for therapeutic
management in the elderly. Neither signs and symp-
toms nor laboratory tests can identify aspiration pneu-
monia74. However, the history of witnessed or suspected
aspiration is the only parameter that restricts antimi-
crobial use in these patients. A reliable selection com-
prises clindamycin, metronidazole or β-lactamase
inhibitor.
MDR organisms are more commonly isolated from
patients with severe chronic underlying disorders and
patients with late-onset HAP75. Having pathogens resis-
tant to the empirical treatment has been independ-
ently associated with mortality62. An initially appropriate
antibiotic regimen could allow reduction of the period
of treatment from the traditional 14–21 days to dura-
tions as short as 7 days, provided that the etiologic
microbe is not P. aeruginosa and that the patient has a
good clinical response with resolution of clinical char-
acteristics of infection63. Elderly patients with multiple
comorbid disorders often recover more slowly. Short-
duration treatment may be suboptimal for patients
with initial treatment not active against the identified
microbes, lung tissue necrosis, bacteremia, S. aureus,
and P. aeruginosa.
Patients superinfected with P. aeruginosa or
Acinetobacter species have a particularly high mortal-
ity, around 90% in some series76. P. aeruginosa and
Acinetobacter are common causes of late-onset pneu-
monia, especially in the ventilated patient. P. aerugi-
nosa has intrinsic resistance to many antimicrobial
agents77. Infection caused by P. aeruginosa is associ-
ated with a significantly higher incidence of therapeu-
tic failure than those caused by other pathogens78.
Treatment should include an antipseudomonal cephalo-
sporin (cefepime, ceftazidime), an antipseudomonal
carbapenem (imipenem or meropenem), β-lactam/β-
lactamase inhibitor (piperacillin–tazobactam) plus an
antipseudomonal fluoroquinolone (ciprofloxacin or
levofloxacin), or aminoglycoside (amikacin, gentam-
icin or tobramycin). Resistant strains of P. aeruginosa
with imipenem-type enzymes and other carbapene-
mases have been reported79. Some MDR pathogens of
P. aeruginosa are susceptible only to polymyxin B.
Some anecdotal experience has led to a recommenda-
tion of aerosolized antibiotics as an adjunct to systemic
treatment in patients with highly resistant P. aeruginosa
pneumonia80. Combination therapy has been contin-
ued for less than the full course of therapy, with cessa-
tion of the aminoglycoside after 5–7 days if the patient
is improving81.
Acinetobacter species are generally less virulent than
P. aeruginosa, but have, nonetheless, become resistant
microbes because of increasing resistance to commonly
used antimicrobial agents. Carbapenem resistance has
been found in 40% of 3,601 isolates of Acinetobacter
baumannii82. The most active agents in vitro are the
polymyxins, i.e., polymyxin B and polymyxin E (colistin).
The nephrotoxicity rates of polymyxin range up to 36%,
and neurotoxicity is currently uncommon83. An alterna-
tive to carbapenem-resistant A. baumannii is combina-
tion therapy with other antibiotics, such as rifampin or
aminoglycosides, sulbactam, ampicillin–sulbactam, and
the polymyxins84,85. Adjunctive treatment with an aero-
solized aminoglycoside or polymyxin for carbapenem-
resistant A. baumannii should be considered, particularly
in patients who are not improving with systemic 
therapy86.
Stenotrophomonas maltophilia, which shares with
Burkholderia cepacia a tendency to colonize the respira-
tory tract rather than cause an invasive disorder, is
uniformly resistant to carbapenems because of a
ubiquitous metallo-β-lactamase. S. maltophilia and 
B. cepacia are most likely to be susceptible to trimetho-
prim–sulfamethoxazole, ticarcillin–clavulanate or a fluo-
roquinolone87. B. cepacia is also commonly susceptible
to ceftazidime and carbapenems.
S. aureus is ubiquitous in critical care areas. More
than 50% of the intensive care unit infections are
caused by MRSA69. Vancomycin has been the accepted
standard for treatment of MRSA. Dosing vancomycin
in patients with fluctuating renal function is difficult
and needs frequent monitoring of levels. There is an
increased risk of nephrotoxicity in patients receiving
vancomycin together with other nephrotoxic agents,
especially aminoglycosides. Combination therapy with
other antimicrobials, such as rifampin and aminogly-
cosides, has been tried but no prospective clinical data
have validated the value of this regimen88. Linezolid
may also be preferred if patients have renal insuffi-
ciency or are taking other nephrotoxic agents. Linezolid
resistance is rare in S. aureus presently89. However, no
firm conclusion can be drawn in considering the use
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of linezolid or a glycopeptide as optimal therapy for
patients with HAP caused by MRSA90.
Legionella pneumophila occurs sporadically but
may be endemic in hospitals with contaminated water
systems or cooling units. The incubation period of
Legionella infection commonly is 2–10 days; infections
that occur more than 10 days after admission are con-
sidered to be nosocomial, and infections that develop
between 4 and 10 days are considered as possibly noso-
comial. The rates of L. pneumophila vary remarkably
between hospitals. It occurs more frequently with sero-
group 1 when the water supply is colonized91. Mono-
therapy with one of the newer macrolides (especially
azithromycin) and the quinolones are effective for
Legionella infection92,93. Other agents include tetracy-
cline, doxycycline, and trimethoprim–sulfamethoxazole.
Combination therapy with rifampin is only recom-
mended in patients for whom standard therapy appears
to be failing94. Patients from long-term care facilities,
patients with a nosocomial infection or patients who
have received transplants should be treated with a flu-
oroquinolone to provide better coverage of other Gram-
negative bacilli. The total course of treatment for
Legionella pneumonia is 7–10 days for azithromycin, 
5 days for levofloxacin (750 mg once daily), and 10–14
days for other medications. Patients who are severely
ill or immunocompromised should receive treatment
for a total duration of 21 days95.
General Prophylaxis
Patients at high risk of HAP include those with abdom-
inal aortic aneurysm repair, thoracic surgery or emer-
gency surgery, general anesthesia, age more than 60
years, totally dependent functional status, weight loss
of more than 10%, use of steroids for chronic diseases,
a recent history of alcohol use, COPD or smoking dur-
ing the preceding year, impaired sensorium, a history
of cerebrovascular disorder with residual neurologic
deficit, low (< 8 mg/dL) or high (> 22 mg/dL) blood urea
nitrogen level, as well as having received more than
four units of blood before operations96. An important
issue that deserves more recognition regarding the
management of HAP in the elderly is prevention.
Effective plans include strict infection control, alcohol-
based hand disinfection, microbiologic surveillance
with timely availability of data on local MDR pathogens,
monitoring and early removal of invasive devices, and
programs to reduce or alter antimicrobial-prescribing
practices.
It is important to preoperatively educate patients at
high risk of developing pneumonia on the postopera-
tive use of incentive spirometry. Taking deep breaths
and becoming mobile as soon as possible in the post-
operative period should also be stressed. Chest physio-
therapy may be of value to patients suffering from or
at risk of HAP, and it might be appropriate to regard it
as a therapeutic option.
Aspiration due to dysphagia is a condition that
must be considered, especially in patients with a cere-
brovascular accident, confusion, alcoholism, and in bed-
ridden patients. A supine position facilitates aspiration,
which may be reduced by semirecumbent positioning97.
Therefore, patients should be managed in a semire-
cumbent position, particularly during feeding. The use
of oral, endotracheal and orogastric tubes, rather than
nasotracheal and nasogastric tubes, can decrease the
frequency of nosocomial sinusitis and possibly pneu-
monia98,99. Parenteral nutrition is associated with a
higher risk of intravascular device-associated infections
and loss of intestinal villous architecture. Enteral nutri-
tion is favored over parenteral nutrition to reduce the
risk of complications24. The rate and volume of enteral
feeding should be adjusted to avoid gastric distension
and to lower the risk of aspiration. A pooled analysis
showed no benefit from post-pyloric versus gastric tube
feeding in critically ill patients100.
Intubation increases the risk of HAP and hence
should be avoided whenever possible19,101. To prevent
HAP, daily interruption or reduction of sedative/paralytic
agents and maintenance of endotracheal cuff pressure
at greater than 20 cmH2O in patients with intubation
is recommended102. Repeat insertion of the endotra-
cheal tube and emergency intubation are risk factors
for pneumonia20,101. Using noninvasive ventilation and
avoiding reintubation after initial extubation may reduce
the risk of HAP. Noninvasive positive pressure ventila-
tion is an alternative for patients with acute exacerba-
tions of COPD or acute hypoxemic respiratory failure,
and for immunosuppressed patients with pulmonary
infiltrates and respiratory failure103,104. A reduced dura-
tion of intubation can be gained by the use of weaning
protocols to reduce the duration of mechanical venti-
latory support and to reduce the risk of HAP105,106.
An inclination to reduce pneumonia with sucral-
fate and to avoid blood transfusion is necessary107.
There is a slightly higher rate of clinically significant
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gastric bleeding when sucralfate is used for stress
bleeding prophylaxis. If necessary, stress bleeding 
prevention with either H2 antagonists or sucralfate is
acceptable22,107. Exposure to blood products is a risk
factor for postoperative infection and postoperative
pneumonia, and the length of time of blood storage is
another factor-modulating risk108,109. Immunosuppres-
sive effects of non-leukocyte-depleted red blood cell
units increase the risk of infection. Leukocyte-depleted
red blood cell transfusions can reduce HAP in selected
patients110. We recommend that to prevent HAP, red
cell transfusions should be avoided if possible and, if
used, should be carried out with fresh red cells111.
Prophylaxis for pneumonia in the elderly, with influ-
enza and pneumococcal vaccination, nutritional meas-
ures and oral hygiene, is important34. Studies in elderly
persons have apparently demonstrated that the poly-
saccharide vaccine prevents an invasive pneumococcal
disorder and assures protection for 5–6 years112. The
pneumococcal vaccine is associated with a decreased
antibody response in the elderly113. Recent findings
have shown that revaccination in elderly people with
the polysaccharide vaccine is safe and may give a fur-
ther immune response114. The pneumococcal polysac-
charide vaccine is suggested for persons > 65 years of
age and particularly for those with selected high-risk co-
existing disorders (chronic cardiovascular disease,
chronic pulmonary diseases, diabetes mellitus, alcohol-
ism, chronic liver disease, or cerebrospinal fluid leaks,
functional or anatomic asplenia, HIV infection, leukemia,
lymphoma, Hodgkin disease, multiple myeloma, gener-
alized malignancy, chronic renal failure, nephrotic
syndrome, or other conditions related to immunosup-
pression, such as solid organ transplantation or human
stem-cell transplantation, and persons receiving immu-
nosuppressive chemotherapy)115. Vaccination may be
carried out either at hospital discharge or during out-
patient treatment. Nutrition is often overlooked in the
elderly with HAP. A low albumin level is a risk factor
for developing pneumonia, and a low body mass
index is associated with a higher mortality rate. A suf-
ficient diet should be recommended, and the nutri-
tional status of patients should be routinely checked.
Conclusion
Pneumonia in the elderly is a very serious condition
that requires swift management. The antibiotic selection
should be made based on the most recent guidelines.
It is important to recognize the variability of bacteriol-
ogy from one hospital to another, specific sites within
the hospital and from one time period to another, and
to use this information to guide the selection of an
appropriate antibiotic treatment regimen. Avoiding
the overuse of antibiotics by tailoring therapy to the
results of lower respiratory tract cultures and shortening
the duration of therapy to the minimal effective period
is required. The application of preventative strategies
aimed at adjustable risk factors should be seriously
considered.
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